Bioequivalence Study of Tretinoin Gel 0.05% to Brand Tretinoin Gel

NCT02249767 | Completed Phase 3 Results DMC

• 1 other identifier: Tret.2014.10.01.14
• Study Type: interventional
• Target: 574
• Locations: 0 countries
• Sites: N/A

Brief Summary

This was a double-blind, randomized, three-treatment, parallel study. Normal, healthy male and female children and adults (i.e., ages 12 to 40 years) with at least Grade 2 (i.e., mild severity) acne vulgaris were treated on the full face once daily for 84 days with the Tretinoin Gel 0.05%, Brand (tretinoin) Gel 0.05%, or Gel Vehicle. Acne lesions were graded by a single blinded observer at screening and at Weeks 0 (i.e., baseline), 2, 4, 8, and 12 at each location.

Conditions

Acne

Outcome Measures

Primary Outcomes (1)

• Percent Change in Baseline Acne Lesions at Week 12

  Percent change in baseline in inflammatory and non-inflammatory lesions at week 12.

  Baseline and 12 weeks

Study Arms (3)

Generic Tretinoin

ACTIVE COMPARATOR

Treatment of acne once daily over 12 weeks

Drug: Tretinoin

Brand Tretinoin

ACTIVE COMPARATOR

Treatment of Acne once daily over 12 weeks

Drug: Tretinoin

Placebo Vehicle

PLACEBO COMPARATOR

Treatment of acne once daily over 12 weeks

Drug: Tretinoin

Interventions

Tretinoin DRUG

Treatment of acne once daily in evening

Also known as: Placebo

Brand Tretinoin; Generic Tretinoin; Placebo Vehicle

Eligibility Criteria

• Age: 12 Years - 40 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Child (0-17), Adult (18-64)

You may qualify if:

• Normal, healthy male and female children and adults aged 12 to 40 years
• Written and verbal informed consent had to be obtained. Subjects aged 12 to 17 years, had to sign an assent for the study and a parent or a legal guardian had to sign the informed consent
• Women of childbearing potential had to be non-pregnant and non-nursing, and had to be willing to avoid pregnancy during the course of the study and during the menstrual cycle following completion of their participation in the study. Adequate contraception was defined as systemic birth control, such as oral contraceptives, for three months prior and implantable/injectable contraceptives (e.g., Norplant, intrauterine device \[IUD\]) for six months prior to study drug administration; or barrier methods, such as diaphragm plus spermicide or condom plus spermicide, consistently for at least 14 days prior to study drug administration; or abstinence.
• On the face, having ≥ 20 inflammatory (i.e., papules and pustules) and ≥ 25 non-inflammatory (i.e., open and closed comedones) lesions with ≤ 2 nodulocystic lesions (i.e, nodules and cysts), as per FDA Draft Guidance on Tretinoin, dated March 20
• Able to refrain from the use of all other topical acne medications or antibiotics during the treatment period
• Considered reliable and capable of understanding their responsibility and role in the study

You may not qualify if:

• Subjects with active cystic acne as evidenced by more than 2 facial nodules. Nodules are defined as in 7.3.3 as: deep-seated in the skin (i.e., centered in the dermis or subcutis) and greater than 5 mm in diameter.
• More than 40 papules and/or pustules (inflammatory lesions).
• More than 60 open and/or closed comedones/milia (non-inflammatory lesions).
• Overall severity grade of less than 2 or greater than 4.
• History of allergy or hypersensitivity to tretinoin, retinoids, or any of the study medication ingredients.
• Significant history or clinical evidence of auto-immune, cardiovascular, gastrointestinal, hematological, hepatic, neurological, pancreatic, or renal disease.
• Use within 6 months prior to baseline of systemic retinoid (isotretinoin) treatment or therapeutic vitamin A supplements of greater than 10,000 units/day (multivitamins are allowed).
• Oral contraceptives started or changed within 3 months prior to study initiation or planned to change during the study.
• Use on the face within 1 month prior to baseline of 1) cryodestruction or chemodestruction, 2) dermabrasion, 3) photodynamic therapy, 4) acne surgery, 5) intralesional steroids, or 6) x-ray therapy.
• Use within 1 month prior to baseline of 1) spironolactone, 2) systemic steroids, 3) systemic antibiotics, 4) systemic treatment for acne vulgaris (other than oral retinoids, which require a 6-month washout), or 5) systemic anti-inflammatory agents.
• Use within 2 weeks prior to baseline of 1) topical steroids, 2) topical retinoids, 3) topical acne treatments including over-the-counter preparations, 4) topical anti-inflammatory agents, or 5) topical antibiotics.
• Pregnant or breast-feeding.
• Serious psychological illness.
• Significant history (within the past year) of alcohol or drug abuse.

Sponsors & Collaborators

• Spear Pharmaceuticals: lead

MeSH Terms

Conditions

Acne Vulgaris

Interventions

Tretinoin

Condition Hierarchy (Ancestors)

Acneiform Eruptions; Skin Diseases; Skin and Connective Tissue Diseases; Sebaceous Gland Diseases

Intervention Hierarchy (Ancestors)

Vitamin A; Retinoids; Carotenoids; Polyenes; Alkenes; Hydrocarbons, Acyclic; Hydrocarbons; Organic Chemicals; Cyclohexenes; Cyclohexanes; Cycloparaffins; Hydrocarbons, Alicyclic; Hydrocarbons, Cyclic; Terpenes; Diterpenes; Pigments, Biological; Biological Factors

Results Point of Contact

• Title: Dr. Spear
• Organization: Spear Pharmaceuticals

spear@spearpharm.com

239-560-2411

Study Officials

• Susan Barker, MD

  Moore Clinical Research

  PRINCIPAL INVESTIGATOR

Publication Agreements

• PI is Sponsor Employee: No
• Restriction Type: OTHER
• Restrictive Agreement: Yes

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 23, 2014
• First Posted: September 26, 2014
• Study Start: November 1, 2013
• Primary Completion: June 1, 2014
• Study Completion: June 1, 2014
• Last Updated: February 10, 2020
• Results First Posted: January 13, 2020

Record last verified: 2020-01